

ASX Announcement | 23 June 2023  
Althea Group Holdings (ASX:AGH)

**Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) ("Act")**

**ALTHEA GROUP HOLDINGS LIMITED** (ASX Code: AGH) ("**Company**") issued 7,244,285 fully paid ordinary shares pursuant to the issue of a conversion notice by Obsidian Global Partners LLC under the convertible securities agreement announced by the Company on 3 February 2023. This reduces the capped maximum number of shares available to the convertible note holder from 43,206,846 to 35,962,561. AGH maintains the option to, at any time prior to the maturity date, redeem some or all of the remaining convertible securities issued by giving notice to the investor (other than in relation to convertible notes the subject of a conversion notice, or if an event of default has occurred).

The Company advises that:

- the shares were issued without disclosure to investors under Part 6D.2 of the Act;
- this notice is being given under section 708A(5)(e) of the Act;
- as at the date of this notice, the Company has complied with:
  - the provisions of Chapter 2M of the Act as they apply to it; and
  - section 674 of the Act; and
- as at the date of this notice, there is no excluded information of the type referred to in subsections 708A(7) and 708A(8) of the Act that is required to be set out in this notice.

**-ENDS-**

*Authorised by: Robert Meissner, Company Secretary*

**For further information, please contact:**

**Althea Group Holdings Ltd**  
**Joshua Fegan**  
CEO & Managing Director  
**M:** 1300 70 20 20  
**E:** [contact@althea.life](mailto:contact@althea.life)

**Media & Investor Enquiries**  
Media & Investor Relations  
**P:** +613 9650 5096  
**E:** [investors@althea.life](mailto:investors@althea.life)



**Althea Group Holdings Limited (ASX:AGH)**

Althea Group Holdings Ltd ('AGH') is a global leader in the manufacturing, sales and distribution of cannabis-based medicines and recreational cannabis products. AGH services these sectors via two distinct business units. Althea, the company's pharmaceutical business, offers a comprehensive range of cannabis-based medicines which are made available to patients via prescription. Peak Processing Solutions, AGH's recreational cannabis business, produces legal cannabis products

